DPP4 and type 2 diabetes mellitus: To date, more than ten inhibitors of DPP-4, such as sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin, have been approved as therapeutic options for the management of patients with T2DM (12, 13).